Your browser doesn't support javascript.
loading
Real-life challenges using personalized prognostic scoring systems in acute myeloid leukemia.
Calleja, Anne; Loschi, Michael; Bailly, Laurent; Morisot, Adeline; Marceau, Alice; Mannone, Lionel; Robert, Guillaume; Auberger, Patrick; Preudhomme, Claude; Raynaud, Sophie; Subtil, Fabien; Sujobert, Pierre; Cluzeau, Thomas.
Afiliación
  • Calleja A; Hematology Department, Cote D'Azur University, Nice Sophia Antipolis University, CHU of Nice, Nice, France.
  • Loschi M; Mediterranean Center for Molecular Medecine, Cote d'Azur University, INSERM U1065, Nice, France.
  • Bailly L; Hematology Department, Cote D'Azur University, Nice Sophia Antipolis University, CHU of Nice, Nice, France.
  • Morisot A; Mediterranean Center for Molecular Medecine, Cote d'Azur University, INSERM U1065, Nice, France.
  • Marceau A; Public Health Department, Centre Hospitalier Universitaire de Nice, Cote d'Azur University, Nice, France.
  • Mannone L; Public Health Department, Centre Hospitalier Universitaire de Nice, Cote d'Azur University, Nice, France.
  • Robert G; CHRU of Lille, Hematology Laboratory, Lille, France.
  • Auberger P; Hematology Department, Cote D'Azur University, Nice Sophia Antipolis University, CHU of Nice, Nice, France.
  • Preudhomme C; Mediterranean Center for Molecular Medecine, Cote d'Azur University, INSERM U1065, Nice, France.
  • Raynaud S; Mediterranean Center for Molecular Medecine, Cote d'Azur University, INSERM U1065, Nice, France.
  • Subtil F; Public Health Department, Centre Hospitalier Universitaire de Nice, Cote d'Azur University, Nice, France.
  • Sujobert P; Cote D'Azur University, Nice Sophia Antipolis University, CHU of Nice, Onco-Hematology Laboratory, Nice, France.
  • Cluzeau T; Hospices Civils de Lyon, Hôpital Lyon Sud, Service d'Hématologie Biologique, Pierre-Bénite, France.
Cancer Med ; 12(5): 5656-5660, 2023 03.
Article en En | MEDLINE | ID: mdl-36394159
ABSTRACT
Personalized medicine is a challenge for patients with acute myeloid leukemia (AML). The identification of several genetic mutations in several AML trials led to the creation of a personalized prognostic scoring algorithm known as the Knowledge Bank (KB). In this study, we assessed the prognostic value of this algorithm on a cohort of 167 real life AML patients. We compared KB predicted outcomes to real-life outcomes. For patients younger than 60-year-old, OS was similar in favorable and intermediate ELN risk category. However, KB algorithm failed to predict OS for younger patients in the adverse ELN risk category and for patients older than 60 years old in the favorable ELN risk category. These discrepancies may be explained by the emergence of several new therapeutic options as well as the improvement of allogeneic stem cell transplantation (aHSCT) outcomes and supportive cares. Personalized medicine is a major challenge and predictions models are powerful tools to predict patient's outcome. However, the addition of new therapeutic options in the field of AML requires a prospective validation of these scoring systems to include recent therapeutic innovations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Humans / Middle aged Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Humans / Middle aged Idioma: En Revista: Cancer Med Año: 2023 Tipo del documento: Article País de afiliación: Francia
...